Immunological mechanisms underlying T1DM pathogenesis
Immunological mechanisms underlying T1DM pathogenesis
批准号:
6421543
负责人:
David Harlan
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Type 1 Diabetes Mellitus (T1DM) is an autoimmune disease resulting from the T cell mediated destruction of insulin-producing beta cells located in the pancreas. Current treatment, which includes insulin replacement by injection, frequent blood glucose monitoring, and dietary/exercise discipline, can prevent death from hormonal insufficiency, but is not curative and does not prevent long-term complications. Those complications include nerve damage and vascular deterioration (large and small blood vessels) resulting in damage to various organs, including the heart, brain, kidneys, and eyes. Life expectancy is shortened by an estimated one-third compared to similar individuals but without T1DM. This work, initiated several years ago at the Naval Medical Research Institute and further developed at the University of Ulm in Germany, has characterized a unique murine model of autoimmune diabetes using rat-insulin promoter (RIP)-CD80 transgenic mice (RIP-CD80 mice). These animals are predisposed to immune mediated beta cell destruction based on their beta cell-specific expression of the costimulatory molecule CD80. While RIP-CD80 mice rarely develop spontaneous diabetes (incidence 6.7%, compared to none of wild type mice), we have observed and have initially characterized the profound susceptibility these mice display to develop progressive islet infiltration and eventually insulin dependent diabetes mellitus (IDDM) following immunization with beta cell autoantigens (i.e. protein molecules that are expressed specifically by the
pancreatic beta cells of these mice). For instance, these animals, unlike non-transgenic littermates, uniformly develop islet cell destruction and IDDM upon immunization with insulin precursors, a beta cell autoantigen strongly suspected to be involved in the pathogenesis of T1DM in humans. Hence, this laboratory's objective using the above mouse model can be summarized as follows:(1) We are preparing to identify self-antigens (Ag) that are thought to be important initial target Ag for the developing autoimmune response. For this purpose, we will simply immunize RIP-CD80 transgenic mice with the various candidate auto-antigenic molecules and then follow them for the development of Ag-specific T cell responses, insulitis, and diabetes.(2) We will study beta cell specific T cell responses in an adoptive transfer model where the primary sensitization of the autoreactive T cells will take place either in vitro, or by immunizing in vivo, as proposed in (1). These studies will focus on the mechanisms of the developing beta cell destructive immune responses, as described in 1) and 2), and will
attempt to identify novel approaches to interfere with the ongoing immune responses.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Secondary Prevention Trials For Recently Diagnosed T1DM
-
批准号:6546668
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:David Harlan
-
依托单位:
Immunological Mechanisms Underlying T1dm Pathogenesis
-
批准号:6821154
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:David Harlan
-
依托单位:
Novel techniques for assessing beta cell turnover
-
批准号:7967592
-
项目类别:
-
资助金额:$22.06万
-
财政年份:--
-
负责人:David Harlan
-
依托单位:
Preclinical studies for measuring beta cell mass in vivo
-
批准号:7734215
-
项目类别:
-
资助金额:$24.85万
-
财政年份:--
-
负责人:David Harlan
-
依托单位:
03-DK-0245 (Effect of AC2993 (synthetic exendin-4) on pancreatic islet function)
-
批准号:7734207
-
项目类别:
-
资助金额:$28.41万
-
财政年份:--
-
负责人:David Harlan
-
依托单位:
Immunological Mechanisms Underlying T1dm Pathogenesis
-
批准号:7734282
-
项目类别:
-
资助金额:$26.39万
-
财政年份:--
-
负责人:David Harlan
-
依托单位:
03-DK-0245 (Effect of AC2993 (synthetic exendin-4) on pancreatic islet function)
-
批准号:7593679
-
项目类别:
-
资助金额:$32.47万
-
财政年份:--
-
负责人:David Harlan
-
依托单位:
Immunological Mechanisms Underlying T1dm Pathogenesis
-
批准号:7593759
-
项目类别:
-
资助金额:$30.19万
-
财政年份:--
-
负责人:David Harlan
-
依托单位:
Assessing a PET-based technique for characterizing beta cell mass in vivo
-
批准号:7593683
-
项目类别:
-
资助金额:$28.42万
-
财政年份:--
-
负责人:David Harlan
-
依托单位:
Rodent pancreatic islet biology in health and disease
-
批准号:8157989
-
项目类别:
-
资助金额:$19.07万
-
财政年份:--
-
负责人:David Harlan
-
依托单位:
Mouse model to assess putative beta cell progenitor cells
-
批准号:8157991
-
项目类别:
-
资助金额:$19.07万
-
财政年份:--
-
负责人:David Harlan
-
依托单位:
Islet Cell Transplantation For T1dm: Clinical Studies
-
批准号:6821150
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:David Harlan
-
依托单位:
T-lymphocyte signaling in autoimumune illness and allogr
-
批准号:6421609
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:David Harlan
-
依托单位:
Mouse model to assess putative beta cell progenitor cells
-
批准号:7967590
-
项目类别:
-
资助金额:$32.09万
-
财政年份:--
-
负责人:David Harlan
-
依托单位:
Rodent pancreatic islet biology in health and disease
-
批准号:7967587
-
项目类别:
-
资助金额:$32.09万
-
财政年份:--
-
负责人:David Harlan
-
依托单位:
Secondary Prevention Trials For Recently Diagnosed Type 1 Diabetes Mellitus
-
批准号:7967701
-
项目类别:
-
资助金额:$42.98万
-
财政年份:--
-
负责人:David Harlan
-
依托单位:
Preclinical studies for measuring beta cell mass in vivo
-
批准号:8157990
-
项目类别:
-
资助金额:$13.11万
-
财政年份:--
-
负责人:David Harlan
-
依托单位:
Immunological Mechanisms Underlying Allograft Rejection
-
批准号:6821167
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:David Harlan
-
依托单位:
Assessing a PET-based technique for characterizing beta cell mass in vivo
-
批准号:7967581
-
项目类别:
-
资助金额:$12.03万
-
财政年份:--
-
负责人:David Harlan
-
依托单位:
Mouse model to assess putative beta cell progenitor cells
-
批准号:7593688
-
项目类别:
-
资助金额:$24.86万
-
财政年份:--
-
负责人:David Harlan
-
依托单位:
海外基金